Change in functional performance · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in global disease severity ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Activity limitations · people with postpolio syndrome
1 finding from 1 review
Adverse events · people with postpolio syndrome
1 finding from 1 review
Sleepiness during the night shift, postintervention; · patients with sleepiness caused by shift work
1 finding from 1 review
Sleep latency MSLT. Scale from: 0 to 20 minutes. · patients with sleepiness caused by shift work
1 finding from 1 review
Sleepiness during the night shift, postintervention; · patients with sleepiness caused by shift work
1 finding from 1 review
Sleep latency MSLT. Scale from: 0 to 20 minutes. · patients with sleepiness caused by shift work
1 finding from 1 review
Fatigue –concentration problems Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Fatigue –reduced motivation Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Fatigue –reduced activity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Fatigue –severity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Adverse events ( · people with a primary brain tumour
It is very uncertain whether boele 2013: modafinil changes adverse events ( compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with a primary brain tumour
1 finding from 1 review
Cognition Symbol Digit Modalities Test (median (range)) · people with a primary brain tumour
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · people with a primary brain tumour
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review